Pulmatrix reports Q3 2022 revenue $1.9M, net loss $5.05M; PUR1900 Phase 2 on track for Q1 2023

Pulmatrix, Inc.

2023-Q3 EPS reported -$4.32 vs consensus -$1.07 ▼ miss (-303.4%)

Revenues $1.9M, up from $1.1M YoY; net loss $5.05M ($1.45 per share) vs $8.18M loss in prior year.
Cash and equivalents $40.7M; expects to fund ops into Q2 2024; raised $1.4M via ATM at ~$5.70/share.
PUR1900 Phase 2 study for ABPA to start dosing in Q1 2023; 16-week regimen.
PUR3100 Phase 1 data for acute migraine anticipated early Q1 2023; database lock in November.
PUR1800 Phase 1b data analysis ongoing for presentation at 2023 medical conference.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Pulmatrix, Inc. reported the three months ended September 30, 2022 results: revenue $1,872, net income $(5,052), EPS $(1.45) per share.

Period: the three months ended September 30, 2022
Revenue: $1,872
Net income: $(5,052)
EPS: $(1.45) per share
Result: reported results

Exact text from the filing

PULMATRIX, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) (in thousands, except share and per share data) Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Revenues $ 1,872 $ 1,069 $ 4,363 $ 4,713 Operating expenses: Research and development 5,287 4,026 13,773 12,423 General and administrative 1,685 1,656 5,212 4,837 Goodwill impairment - 3,577 - 3,577 Total operating expenses 6,972 9,259 18,985 20,837 Loss from operations (5,100 ) (8,190 ) (14,622 ) (16,124 ) Other income (expense), net: Interest income 102 1 118 6 Other (expense) income, net (54 ) 5 (116 ) (22 ) Total other income (expense), net 48 6 2 (16 ) Net loss $ (5,052 ) $ (8,184 ) $ (14,620 ) $ (16,140 ) Net loss per share attributable to common stockholders – basic and diluted $ (1.45 ) $ (2.91 ) $ (4.32 ) $ (6.08 )

View on SEC.gov

Browse all earnings releases →

Pulmatrix, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-031516

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.